Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 21 June 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Iron reduction improves interferon therapy response in chronic hepatitis C patients

Iron removal by phlebotomy improves the rate of response to interferon therapy in patients with chronic hepatitis C, claim researchers from Italy.

News image

fiogf49gjkf04

The team evaluated whether iron reduction by phlebotomy, before interferon-alpha therapy, improves virological sustained response in previously untreated, non-cirrhotic patients with chronic hepatitis C.

The findings of the research were published in the May issue of the American Journal of Gastroenterology.

A total of 114 hepatitis C virus (HCV) RNA-positive patients with hepatic iron concentrations of ≥ 700 µg/g dry wt (men) and ≥ 500 µg/g dry wt (women) were included in the study.

They were stratified according to HCV genotype and gamma-glutamyltransferase values.

The patients were then randomly allocated to interferon alone (6 MU, 3 times a week, Group A) or to phlebotomy until iron depletion followed by interferon (6 MU, 3 times a week, Group B).

After 4 months, the dosage was reduced to 3 MU, 3 times a week, for another 8 months.

Virological sustained response was observed in 25 patients (22%) - 9 (16%) of Group A and 16 (28%) of Group B.

At univariate analysis, the variables found to be associated with the response were HCV genotypes 2-3 and normal gamma-glutamyltransferase.

Higher levels of baseline ALT, normal ALT values, and negativity for HCV-RNA at the 3rd month of therapy were also linked with response.

At multivariate analysis, HCV genotype and ALT levels at enrollment maintained their association with the response.

Iron reduction improved response to interferon therapy by over 2-fold.
American Journal of Gastroenterology

The authors discovered that a trend toward a better response to interferon was observed in patients who received phlebotomy (odds ratio = 2.32).

Furthermore, patients with hepatic iron concentration of ≤ 1100 µg/g dry wt had a trend toward a higher rate of virological sustained response when submitted to treatment B.

Silvia Fargion, of the University of Milan, concluded on behalf of fellow authors, "Iron removal by phlebotomy is able to improve the rate of response to interferon, especially in patients with lower hepatic iron deposits.

"It could be useful as adjuvant therapy to new therapeutic modalities."

In an accompanying Editorial, Steven I. Shedlofsky, of the University of Kentucky, Lexington, Kentucky, USA, comments, "The role for routine iron reduction in the therapy of hepatitis C patients remains controversial and is not advocated or mentioned in current reviews of HCV therapy.

"This may be because modern evidence-based medicine requires stronger proof of efficacy than what is currently published, and cannot recommend based on the purely theoretical benefits of iron reduction."

"However, there may also be a bias against using therapies for hepatitis C that are not directed at eradication of virus," he adds.

Nonetheless, in the absence of "official" recommendations, Dr Shedlofsky advocates phlebotomy in all non-acutely ill HCV patients with serum ferritins of < 200 ng/ml.

He concludes that, "Iron reduction using phlebotomy as non-eradicative therapy is safe and relatively inexpensive. It offers potential benefit even if the patient is not a candidate for, cannot tolerate, or failed interferon-ribavirin therapy."

Am J Gastroenterol 2002; 97(5): 1093-6, 1204-10
07 June 2002

Go to top of page Email this page Email this page to a colleague

 31 May 2018 
Diagnostic for NAFLD  
 31 May 2018 
Bile acids and the risks for hepatotoxicity
 31 May 2018 
Rectal cancer female sexuality score
 30 May 2018 
Fungal dysbiosis in cirrhosis
 30 May 2018 
Placebo rates in ulcerative colitis trials
 30 May 2018 
Follow-up testing and colorectal cancer mortality
 29 May 2018 
Organ transplantation donors
 29 May 2018 
Novel therapies for IBD
 29 May 2018 
Helicobacter pylori infection to stomach cancer
 28 May 2018 
Mesalazine in ulcerative colitis
 28 May 2018 
Technology and management of digestive diseases
 28 May 2018 
Therapeutic strategies for HCV
 25 May 2018 
Post‐operative complications in elderly IBD
 25 May 2018 
Technology to increase colorectal cancer screening
 25 May 2018 
Colorectal cancer–specific mortality
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Precision medicine for tumors
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
New therapies for CDI
 15 May 2018 
Hep B in the Grey Zone
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Chronic Hep B
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Symptom assessment in cirrhotic ascites
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
European guidelines on pancreatic cystic neoplasms

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us